0001209191-19-041297.txt : 20190703 0001209191-19-041297.hdr.sgml : 20190703 20190703200020 ACCESSION NUMBER: 0001209191-19-041297 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190702 FILED AS OF DATE: 20190703 DATE AS OF CHANGE: 20190703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Berg Aaron CENTRAL INDEX KEY: 0001770259 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21392 FILM NUMBER: 19943009 MAIL ADDRESS: STREET 1: C/O AMARIN PHARMA, INC. STREET 2: 1430 ROUTE 206 CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMARIN CORP PLC\UK CENTRAL INDEX KEY: 0000897448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 6699 020 MAIL ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC DATE OF NAME CHANGE: 20000201 FORMER COMPANY: FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC DATE OF NAME CHANGE: 19930322 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-07-02 0 0000897448 AMARIN CORP PLC\UK AMRN 0001770259 Berg Aaron C/O AMARIN PHARMA, INC. 1430 ROUTE 206 BEDMINSTER NJ 07921 0 1 0 0 CHIEF COMMERCIAL OFFICER Ordinary Shares 2019-07-02 4 M 0 69564 2.50 A 105915 D Ordinary Shares 2019-07-02 4 S 0 50000 20.4616 D 55915 D Ordinary Shares 2019-07-02 4 S 0 19564 21.42 D 36351 D Ordinary Shares 2019-07-03 4 M 0 29250 2.80 A 65601 D Ordinary Shares 2019-07-03 4 S 0 29250 22.6406 D 36351 D Stock Option (Right to Buy) 2.50 2019-07-02 4 M 0 69564 0.00 D 2025-07-06 Ordinary Shares 69564 49998 D Stock Option (Right to Buy) 2.80 2019-07-03 4 M 0 29250 0.00 D 2028-05-01 Ordinary Shares 29250 87750 D The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Please see the section title "Remarks" below for additional information. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.32 to $20.675, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.62 to $22.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. On July 6, 2015, the Reporting Person was granted an option to purchase 400,000 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on July 31, 2015. On May 1, 2018, the Reporting Person was granted an option to purchase 117,000 Ordinary Shares under the Plan. The shares subject to this option shall vest as follows: 25% of the total number of underlying shares shall vest on May 1, 2019, and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months. In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 969,186 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and Restricted Stock Units granted under the Plan including but not limited to, certain performance-based Restricted Stock Units that are earned only if product revenues reach pre-defined annual milestone levels ranging from $300 million to $1.0 billion and, in certain cases, then vest only if the recipient remains with the company for an extended period of time. /s/ Joseph Kennedy, by power of attorney 2019-07-03